Rental revenue of $5.4 million, down 34.1% from the same period in
2016

GAAP net loss of $0.6 million, reflecting a $5.9 million decrease from
the same period in 2016

Non-GAAP net income of $7.0 million, reflecting a 32.5% increase over
the same period in 2016 and a 10.9% return on revenue (see
accompanying table for reconciliation of GAAP and non-GAAP measures)

Adjusted EBITDA of $11.6 million, representing 5.8% growth over the
same period in 2016 and an 18.1% return on revenue (see accompanying
table for reconciliation of GAAP and non-GAAP measures)

Total units sold were 34,000, an increase of 10,700, or 45.9%, over
the same period in 2016

Full Year 2017 Highlights

Record total revenue of $249.4 million, up 23.0% versus 2016

Record sales revenue of $225.5 million, up 34.1% versus 2016

Rental revenue of $23.9 million, down 30.9% versus 2016

GAAP net income of $21.0 million, up 2.4% versus 2016

Record non-GAAP net income of $28.6 million, reflecting a 39.3%
increase versus 2016 and an 11.5% return on revenue

Record Adjusted EBITDA of $50.8 million, representing a 17.2% increase
versus 2016 and a 20.4% return on revenue

Record units sold of 128,000, an increase of 36,000, or 39.1%, versus
2016

263 inside direct-to-consumer sales representatives as of December 31,
2017, an increase of 86 or 48.6% versus December 31, 2016

“The fourth quarter of 2017 was another successful quarter for us,
driven by record sales in our domestic direct-to-consumer channel and
strong sales in our domestic business-to-business channel,” said Chief
Executive Officer, Scott Wilkinson. “We are executing on our strategic
initiatives and remain focused on increasing adoption of our
best-in-class oxygen product offerings across all of our sales channels.
We believe we should see strong sales growth in 2018 as portable oxygen
concentrator penetration increases worldwide. In the fourth quarter of
2017, we continued hiring in our Cleveland facility primarily to expand
our direct-to-consumer sales team. In support of our European customers,
we began production of our Inogen One G3 concentrators with our new
Czech Republic-based contract manufacturing partner, Foxconn.”

Fourth Quarter 2017 Financial Results

Total revenue for the three months ended December 31, 2017 rose 25.4% to
$63.8 million from $50.9 million in the same period in 2016.
Direct-to-consumer sales rose 57.5% over the same period in 2016, ahead
of our expectations and primarily due to an increase in the number of
sales representatives, marketing expenditures, and sales representative
productivity. Domestic business-to-business sales also exceeded our
expectations and grew 46.1% over the same period in 2016, primarily
driven by continued strong demand from our private label partner and
traditional home medical equipment providers. International
business-to-business sales in the fourth quarter of 2017 declined 0.8%
from the comparative period in 2016, primarily due to no major European
tenders being awarded to our provider partners in the fourth quarter of
2017. Additionally, the fourth quarter of 2016 included sizeable unit
orders from South Korea that did not repeat in the fourth quarter of
2017, creating a difficult comparable. Sales in Europe represented 84.3%
of international sales in the fourth quarter of 2017, up from 83.3% in
the fourth quarter of 2016. Rental revenue in the fourth quarter of 2017
was $5.4 million compared to $8.2 million in the fourth quarter of 2016,
representing a decline of 34.1% from the same period in the prior year,
primarily due to the $2.0 million rental benefit recorded in the fourth
quarter of 2016 associated with the 21st Century Cures Act (Cures Act),
which increased reimbursement rates retrospectively for some Medicare
beneficiaries, and our continued focus on direct-to-consumer sales
versus rentals. Rental revenue declined to 8.5% of total revenue in the
fourth quarter of 2017 from 16.2% of total revenue in the fourth quarter
of 2016.

Total gross margin was 48.2% in the fourth quarter of 2017 versus 48.5%
in the comparative period in 2016. The decrease in total gross margin
was primarily due to the $2.0 million Cures Act benefit recorded in the
fourth quarter of 2016, which contributed 2.1% to total gross margin in
the fourth quarter of 2016. Sales gross margin was 50.5% in the fourth
quarter of 2017 versus 49.9% in the fourth quarter of 2016. The
sales gross margin percentage improvement was primarily attributable to
an increased sales mix towards direct-to-consumer sales and lower cost
of goods sold per unit, mostly due to lower materials costs, partially
offset by decreased average selling prices. Rental gross margin was
23.2% in the fourth quarter of 2017 versus 41.4% in the fourth quarter
of 2016. The decrease in rental gross margin was primarily due to the
$2.0 million Cures Act benefit recorded in the fourth quarter of 2016,
which contributed 19.2% to rental gross margin in the fourth quarter of
2016.

Total operating expense increased to $25.6 million, or 40.1% of revenue,
in the fourth quarter of 2017 versus $18.5 million, or 36.4% of revenue,
in the fourth quarter of 2016 as the Company continued to make
investments it expects will increase future revenue growth.

Operating expense included research and development expense of $1.4
million in the fourth quarter of 2017, which was up slightly from the
$1.2 million recorded in the comparative period in 2016, primarily due
to increased product development expenses. Sales and marketing expense
increased to $15.2 million in the fourth quarter of 2017 versus $9.3
million in the comparative period in 2016, primarily due to increased
advertising expense and increased personnel-related expenses due to
salesforce additions. General and administrative expense increased to
$9.0 million in the fourth quarter of 2017 versus $8.0 million in the
comparative period in 2016, primarily due to increased personnel-related
expenses.

In the fourth quarter of 2017, Inogen’s provision for income taxes
totaled $6.4 million, representing an effective tax rate of 110.5%. In
the fourth quarter of 2016, Inogen’s provision for income taxes totaled
$0.6 million, representing an effective tax rate of 9.8%. As a result of
the Tax Cuts and Jobs Act (TCJA) enacted on December 22, 2017, Inogen
reported a $7.6 million non-cash income tax provision expense associated
with the revaluation of the deferred tax asset. Our effective tax rate
in the fourth quarter of 2017 also included a $3.5 million decrease in
provision for income taxes related to excess tax benefits recognized
from stock-based compensation compared to $1.7 million in the fourth
quarter of 2016. Excluding both the deferred tax asset revaluation
expense and the stock-based compensation benefit, Inogen’s non-GAAP
effective tax rate in the fourth quarter of 2017 was 40.0% versus 39.7%
in the fourth quarter of 2016.

As a result of the TCJA, Inogen reported a GAAP net loss of $0.6 million
in the fourth quarter of 2017, primarily due to the $7.6 million
non-cash income tax provision expense associated with the revaluation of
the Company’s noncurrent deferred tax asset. Non-GAAP net income for the
fourth quarter of 2017 increased 32.5% to $7.0 million from $5.3 million
in the fourth quarter of 2016.

Adjusted EBITDA for the three months ended December 31, 2017 rose 5.8%
to $11.6 million, or 18.1% of revenue, from $10.9 million, or 21.5% of
revenue, in the fourth quarter of 2016.

Cash, cash equivalents, and marketable securities were $173.9 million as
of December 31, 2017 compared to $163.1 million as of September 30,
2017, an increase of $10.9 million in the fourth quarter of 2017.

Financial Outlook for 2018

Inogen is increasing its full year 2018 total revenue guidance range to
$298 to $308 million, up from $295 to $305 million, representing growth
of 19.5% to 23.5% versus 2017 full year results. The Company expects
direct-to-consumer sales to be its fastest growing channel, domestic
business-to-business sales to have a solid growth rate, and
international business-to-business sales to have a modest growth rate,
where the strategy will continue to be heavily focused on the European
markets. Inogen expects rental revenue to be relatively flat in 2018
compared to 2017 as the Company continues to focus on sales versus
rentals.

Further, the Company is also increasing its full year 2018 GAAP net
income and non-GAAP net income guidance range to $36 to $39 million, up
from $31 to $35 million, representing growth of 71.4% to 85.7% compared
to 2017 GAAP net income of $21.0 million and growth of 26.0% to 36.5%
compared to 2017 non-GAAP net income of $28.6 million. The Company
estimates that the decrease in provision for income taxes related to
excess tax benefits recognized from stock-based compensation will lead
to a decrease in provision for income taxes of approximately $8.0
million in 2018 based on forecasted stock activity, which would lower
its effective tax rate as compared to the U.S. statutory rate. Excluding
the $8.0 million decrease in provision for income taxes expected in
2018, the Company expects an effective tax rate of approximately 25%,
down from its previous estimate of 37% due to the TCJA. The Company
expects its effective tax rate including stock compensation deductions
to vary quarter-to-quarter depending on the amount of pre-tax net income
and on the timing and size of stock option exercises.

Inogen is maintaining its guidance range for full year 2018 Adjusted
EBITDA of $60 to $64 million, representing 18.0% to 25.9% growth
compared to 2017 results.

Inogen also expects net positive cash flow for 2018 with no additional
equity capital required to meet its current operating plan.

Conference Call

Individuals interested in listening to the conference call today at
1:30pm PT/4:30pm ET may do so by dialing (855) 238-8123 for domestic
callers or (412) 317-5217 for international callers. Please reference
Inogen (INGN) to join the call. To listen to a live webcast, please
visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/.

A replay of the call will be available beginning February 27, 2018 at
3:30pm PT/6:30pm ET through 3:30pm PT/6:30pm ET on March 6, 2018. To
access the replay, dial (877) 344-7529 or (412) 317-0088 and reference
Access Code: 10116324. The webcast will also be available on Inogen's
website for one year following the completion of the call.

Inogen has used, and intends to continue to use, its Investor Relations
website, http://investor.inogen.com/,
as a means of disclosing material non-public information and for
complying with its disclosure obligations under Regulation FD. For more
information, visit http://investor.inogen.com/.

About Inogen

Inogen is innovation in oxygen therapy. We are a medical technology
company that develops, manufactures and markets innovative oxygen
concentrators used to deliver supplemental long-term oxygen therapy to
patients suffering from chronic respiratory conditions.

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, among others, statements regarding anticipated growth
opportunities; expectations for all revenue channels for full year 2018;
the expected impact of the decrease in provision for income taxes
related to excess tax benefits recognized from stock-based compensation
for full year 2018; and financial guidance for 2018, including revenue,
GAAP net income, Adjusted EBITDA, non-GAAP net income, net cash flow,
effective tax rates, and the need for equity financing. Forward-looking
statements are subject to numerous risks and uncertainties that could
cause actual results to differ materially from currently anticipated
results, including but not limited to, risks arising from the
possibility that Inogen will not realize anticipated revenue; the impact
of reduced reimbursement rates, including private payor reductions and
reductions in connection with competitive bidding and the Center for
Medicare and Medicaid Services (CMS) rules; the possible loss of key
employees, customers, or suppliers; and intellectual property risks if
Inogen is unable to secure and maintain patent or other intellectual
property protection for the intellectual property used in its products.
In addition, Inogen's business is subject to numerous additional risks
and uncertainties, including, among others, risks relating to market
acceptance of its products; competition; its sales, marketing and
distribution capabilities; its planned sales, marketing, and research
and development activities; interruptions or delays in the supply of
components or materials for, or manufacturing of, its products; seasonal
variations; unanticipated increases in costs or expenses; and risks
associated with international operations. Information on these and
additional risks, uncertainties, and other information affecting
Inogen’s business operating results are contained in its Quarterly
Report on Form 10-Q for the quarter ended September 30, 2017 and in its
other filings with the Securities and Exchange Commission. Additional
information will also be set forth in Inogen’s Annual Report on Form
10-K for the year ended December 31, 2017 to be filed with the
Securities and Exchange Commission. These forward-looking statements
speak only as of the date hereof. Inogen disclaims any obligation to
update these forward-looking statements except as may be required by law.

Use of Non-GAAP Financial Measures

Inogen has presented certain financial information in accordance with
U.S. GAAP and also on a non-GAAP basis for the three and twelve months
ended December 31, 2017 and December 31, 2016. Management believes that
non-GAAP financial measures, taken in conjunction with U.S. GAAP
financial measures, provide useful information for both management and
investors by excluding certain non-cash and other expenses that are not
indicative of Inogen's core operating results. Management uses non-GAAP
measures to compare Inogen's performance relative to forecasts and
strategic plans, to benchmark Inogen's performance externally against
competitors, and for certain compensation decisions. Non-GAAP
information is not prepared under a comprehensive set of accounting
rules and should only be used to supplement an understanding of Inogen's
operating results as reported under U.S. GAAP. Inogen encourages
investors to carefully consider its results under U.S. GAAP, as well as
its supplemental non-GAAP information and the reconciliation between
these presentations, to more fully understand its business.
Reconciliations between U.S. GAAP and non-GAAP results are presented in
the accompanying table of this release. For future periods, Inogen is
unable to provide a reconciliation of non-GAAP measures without
unreasonable effort as a result of the uncertainty regarding, and the
potential variability of, the amounts of interest income, interest
expense, depreciation and amortization, stock-based compensation,
provisions for income taxes, and certain other infrequently occurring
items, such as acquisition related costs, that may be incurred in the
future.

Consolidated Balance Sheets

(unaudited)

(amounts in thousands)

December 31,

2017

2016

Assets

Current assets

Cash and cash equivalents

$

142,953

$

92,851

Marketable securities

30,991

21,033

Accounts receivable, net

31,444

30,828

Inventories, net

18,842

14,343

Deferred cost of revenue

361

398

Income tax receivable

1,313

433

Prepaid expenses and other current assets

2,584

1,659

Total current assets

228,488

161,545

Property and equipment, net

20,103

25,199

Goodwill

2,363

—

Intangible assets, net

4,717

241

Deferred tax asset - noncurrent

18,636

26,654

Other assets

765

410

Total assets

$

275,072

$

214,049

Liabilities and stockholders' equity

Current liabilities

Accounts payable and accrued expenses

$

20,626

$

12,795

Accrued payroll

6,877

6,123

Warranty reserve - current

2,505

1,688

Deferred revenue - current

3,533

2,239

Income tax payable

345

—

Total current liabilities

33,886

22,845

Warranty reserve - noncurrent

3,666

1,792

Deferred revenue - noncurrent

9,402

7,042

Deferred tax liability - noncurrent

348

—

Other noncurrent liabilities

729

282

Total liabilities

48,031

31,961

Stockholders' equity

Common stock

21

20

Additional paid-in capital

218,109

194,466

Retained earnings (accumulated deficit)

8,639

(12,363

)

Accumulated other comprehensive income (loss)

272

(35

)

Total stockholders' equity

227,041

182,088

Total liabilities and stockholders' equity

$

275,072

$

214,049

Consolidated Statements of Comprehensive Income

(unaudited)

(amounts in thousands, except share and per share amounts)

Three months ended

Twelve months ended

December 31,

December 31,

2017

2016

2017

2016

Revenue

Sales revenue

$

58,351

$

42,604

$

225,492

$

168,170

Rental revenue

5,436

8,247

23,946

34,659

Total revenue

63,787

50,851

249,438

202,829

Cost of revenue

Cost of sales revenue

28,856

21,330

110,163

85,154

Cost of rental revenue, including depreciation of $2,258 and
$2,696 for the three months ended and $9,835 and $11,429 for the
twelve months ended, respectively

4,175

4,833

18,038

20,365

Total cost of revenue

33,031

26,163

128,201

105,519

Gross profit

30,756

24,688

121,237

97,310

Operating expense

Research and development

1,369

1,216

5,313

5,113

Sales and marketing

15,189

9,320

50,758

37,540

General and administrative

9,008

7,981

37,576

31,793

Total operating expense

25,566

18,517

93,647

74,446

Income from operations

5,190

6,171

27,590

22,864

Other income (expense)

Interest expense

—

—

—

(6

)

Interest income

297

70

765

196

Other income (expense)

307

(407

)

1,301

(329

)

Total other income (expense), net

604

(337

)

2,066

(139

)

Income before provision for income taxes

5,794

5,834

29,656

22,725

Provision for income taxes

6,400

574

8,654

2,206

Net income (loss)

$

(606

)

$

5,260

$

21,002

$

20,519

Other comprehensive income (loss), net of tax

Change in foreign currency translation adjustment

51

—

363

—

Change in net unrealized gains (losses) on foreign currency hedging

(125

)

79

(567

)

55

Less: reclassification adjustment for net (gains) losses included in
net income

Basic net income (loss) per share attributable to common
stockholders(1)

$

(0.03

)

$

0.26

$

1.02

$

1.02

Diluted net income (loss) per share attributable to common
stockholders(1)

$

(0.03

)

$

0.25

$

0.96

$

0.97

Weighted-average number of shares used in calculating net
income (loss) per share attributable to common stockholders:

Basic common shares

20,869,589

20,310,857

20,683,807

20,067,152

Diluted common shares

22,167,358

21,362,513

21,897,988

21,095,867

(1) Reconciliations of net income (loss) attributable to common
stockholders basic and diluted can be found in Inogen’s Annual
Report on Form 10-K to be filed with the Securities and Exchange
Commission.

Supplemental Financial Information

(unaudited)

(in thousands, except units and patients)

Three months ended

Twelve months ended

December 31,

December 31,

2017

2016

2017

2016

Revenue by region and category

Business-to-business domestic sales

$

21,856

$

14,958

$

83,390

$

56,605

Business-to-business international sales

11,991

12,091

55,519

50,106

Direct-to-consumer domestic sales

24,504

15,555

86,583

61,459

Direct-to-consumer domestic rentals

5,436

8,247

23,946

34,659

Total revenue

$

63,787

$

50,851

$

249,438

$

202,829

Additional financial measures

Units sold

34,000

23,300

128,000

92,000

Net rental patients as of period-end

30,700

33,300

30,700

33,300

Reconciliation of U.S. GAAP to Other Non-GAAP Financial Measures

(unaudited)

(in thousands)

Three months ended

Twelve months ended

December 31,

December 31,

Non-GAAP EBITDA and Adjusted EBITDA

2017

2016

2017

2016

Net income (loss)

$

(606

)

$

5,260

$

21,002

$

20,519

Non-GAAP adjustments:

Interest expense

—

—

—

6

Interest income

(297

)

(70

)

(765

)

(196

)

Provision for income taxes

6,400

574

8,654

2,206

Depreciation and amortization

3,045

3,268

12,302

13,558

EBITDA (non-GAAP)

8,542

9,032

41,193

36,093

Stock-based compensation

3,010

1,890

9,640

7,294

Adjusted EBITDA (non-GAAP)

$

11,552

$

10,922

$

50,833

$

43,387

Three months ended

Twelve months ended

December 31,

December 31,

Non-GAAP net income

2017

2016

2017

2016

Net income (loss)

$

(606

)

$

5,260

$

21,002

$

20,519

Non-GAAP adjustments:

2017 U.S. tax reform(1)

7,578

—

7,578

—

Non-GAAP net income

$

6,972

$

5,260

$

28,580

$

20,519

Three months ended

Twelve months ended

December 31,

December 31,

Non-GAAP operating expense

2017

2016

2017

2016

Operating expense

$

25,566

$

18,517

$

93,647

$

74,446

Non-GAAP adjustments:

Litigation settlement benefit (expense), net (2)

(100

)

110

(576

)

202

Operating expense, excluding certain operating expenses (non-GAAP)

$

25,466

$

18,627

$

93,071

$

74,648

Three months ended

Twelve months ended

December 31,

December 31,

Non-GAAP - sales, general & administrative (SG&A) expense

2017

2016

2017

2016

SG&A expense

$

24,197

$

17,301

$

88,334

$

69,333

Non-GAAP adjustments:

Litigation settlement benefit (expense), net (2)

(100

)

110

(576

)

202

SG&A expense, excluding certain operating expenses (non-GAAP)

$

24,097

$

17,411

$

87,758

$

69,535

(1) On December 22, 2017, the Tax Cuts and Jobs Act
(TCJA) was enacted into law, which significantly changes existing
U.S. tax law and includes numerous provisions that affect the
Company. During the fourth quarter of 2017, the Company recorded
an estimated one-time net charge due to the impact of changes in
the tax rate, primarily on deferred tax assets.

(2) Amounts in 2017 consist of a patent litigation
settlement expense, net of a benefit, in the third and fourth
quarters. Amounts in 2016 consist of a patent litigation
settlement benefit partially offset by a litigation expense
associated with a labor law class-action lawsuit that was accrued
in the first quarter of 2016 and paid in the fourth quarter of
2016.

Three months ended

Twelve months ended

December 31,

December 31,

Non-GAAP provision for income taxes and effective tax rate

2017

2016

2017

2016

Income before provision for income taxes

$

5,794

$

5,834

$

29,656

$

22,725

Provision for income taxes

6,400

574

8,654

2,206

Effective tax rate

110.5

%

9.8

%

29.2

%

9.7

%

Provision for income taxes

$

6,400

$

574

$

8,654

$

2,206

Non-GAAP adjustments:

Excess tax benefits from stock-based compensation

3,495

1,745

9,936

6,042

2017 U.S. tax reform (1)

(7,578

)

—

(7,578

)

—

Provision for income taxes (non-GAAP)

$

2,317

$

2,319

$

11,012

$

8,248

Income before provision for income taxes

$

5,794

$

5,834

$

29,656

$

22,725

Provision for income taxes (non-GAAP)

2,317

2,319

11,012

8,248

Effective tax rate (non-GAAP)

40.0

%

39.7

%

37.1

%

36.3

%

(1) On December 22, 2017, the Tax Cuts and Jobs Act
(TCJA) was enacted into law, which significantly changes existing
U.S. tax law and includes numerous provisions that affect the
Company. During the fourth quarter of 2017, the Company recorded
an estimated one-time net charge due to the impact of changes in
the tax rate, primarily on deferred tax assets.

Company

Follow Us

TERMS AND CONDITIONS OF USE

The investor relations site ("Site") with which this document is associated is maintained by S&P Global Market Intelligence ("S&P") on behalf of the organization featured on the Site (S&P's "Client"). These Terms and Conditions of Use ("Terms of Use") set forth the terms on which you may use the Site, and the information and materials contained therein (the "Contents"). By using the Site, you agree to these Terms of Use. If you do not agree to these Terms of Use, you are not authorized to use the Site or Contents in any manner, and you should immediately discontinue any use of the Site or the Contents.

S&P and/or its Client shall have the right at any time to modify or discontinue any aspect of the Site or any part of the Contents. S&P may also modify these Terms of Use without notice. You agree to monitor these Terms of Use, and to cease all access or use of the Site if you no longer agree to abide by the Terms of Use. Your continued use of the Site shall constitute acceptance of such modification.

S&P and the Client grant to you a limited, personal license to access the Site and to access and download the Contents, but only for your own personal, family and household use. You may not use, reproduce, distribute or display any portion of the Site for any other purpose, including without limit any commercial purpose. You may use the Site and the Contents for lawful purposes only. S&P and Client reserve all rights not expressly granted, including the right to terminate your use of the Site without notice.

The Site contains copyrighted material, trademarks and service marks, and other proprietary information, including but not limited to text, software, and graphics, which materials are owned by S&P and/or its Client. S&P and Client reserve all rights in the Contents. You agree not to reproduce, distribute, sell, broadcast, publish, retransmit, disseminate, circulate or commercially exploit the Site or the Contents without the express written consent of S&P and the Client.

You agree to access the Contents and the Site manually, by request, and not automatically, through the use of a program, or other means. You agree not to take any action, alone or with others, that would interfere with the operation of the Site, to alter the Site in any way, or to impede others' access to and freedom to enjoy and use the Site as made available by S&P and S&P’s Client.

THE SITE AND THE CONTENTS ARE PROVIDED ON AN "AS IS" BASIS. S&P, ITS CLIENT, AND ANY OTHER PROVIDERS OF THE INFORMATION EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF ACCURACY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.

NEITHER, S&P, THE CLIENT NOR EITHER OF THEIR AFFILIATES, SHAREHOLDERS, OFFICERS, EMPLOYEES, AGENTS OR REPRESENTATIVES SHALL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, EXEMPLARY , PUNITIVE SPECIAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR RELATING TO THE SITE, THE USE OF OR INABILITY TO USE THE SITE, OR THE CONTENTS, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN PARTICULAR, S&P WILL NOT BE LIABLE FOR ANY LOSS OR DAMAGE CAUSED BY YOUR RELIANCE ON INFORMATION OBTAINED THROUGH THE SITE.

It is your responsibility to evaluate the accuracy, completeness or usefulness of any of the Contents available on the Site. Please seek the advice of professionals regarding the evaluation of any of the information on the Site.

The Site does not represent an offer or solicitation with respect to the purchase or sale of any security.

These Terms of Use are the entire agreement between the parties with respect to its subject matter, and it can be amended only via written agreement by S&P. These terms and conditions shall be governed by the law of New York, without regard to principals of conflicts or choice of laws.

Specifications apply to all new retail units sold after December 7th 2015.

Specifications for rental units through insurance may vary.

1By submitting this information, I authorize Inogen to contact me, including by phone.